SR One leads the $37.5m B round for the gene therapy company with existing corporate investor MedImmune Ventures also investing.

Applied Genetic Technologies Corp. (AGTC), a US-based biotechnology company that receives much of its technology licenced from the University of Florida, has raised a $37.5m series B round. GlaxoSmithKline’s venture unit SR One led the round along with life science venture firm Alta Partners. They were joined by new investor Osage University Partners, a venture…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.